Business Description
ImageneBio Inc
NAICS : 541714
SIC : 2834
ISIN : US45175G2075
Total Employee Number:
17Description
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 48.51 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.05 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 0.21 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 24.52 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.86 | |||||
9-Day RSI | 42.28 | |||||
14-Day RSI | 44.68 | |||||
3-1 Month Momentum % | 5.08 | |||||
6-1 Month Momentum % | -16.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 18.39 | |||||
Quick Ratio | 18.39 | |||||
Cash Ratio | 17.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | 8.09 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -2752.25 | |||||
OCF Margin % | -2752.25 | |||||
ROE % | -32.03 | |||||
ROA % | -28.17 | |||||
ROIC % | -258.43 | |||||
ROC (Joel Greenblatt) % | -5126.08 | |||||
ROCE % | -33.58 | |||||
Moat Score | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 34.09 | |||||
PB Ratio | 0.51 | |||||
Price-to-Tangible-Book | 0.51 | |||||
EV-to-EBIT | 1.1 | |||||
EV-to-EBITDA | 1.11 | |||||
EV-to-Revenue | -64.68 | |||||
EV-to-FCF | 2.35 | |||||
| Price-to-Net-Current-Asset-Value | 0.58 | |||||
| Price-to-Net-Cash | 0.61 | |||||
Earnings Yield (Greenblatt) % | 90.91 | |||||
FCF Yield % | -34.92 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ImageneBio Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.8 | ||
| EPS (TTM) ($) | -4.478 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 44.68 | ||
| 14-Day ATR ($) | 0.331582 | ||
| 20-Day SMA ($) | 5.86125 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 3.94 - 18 | ||
| Shares Outstanding (Mil) | 11.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ImageneBio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ImageneBio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 108 days | ||
| Second quarter earnings results for 2026 | 2026-07-24 | 5.57 (+0.72%) | ||
| General meeting for 2026 | 2026-06-16 09:00 | 5.54 (-4.48%) | ||
| Jefferies Global Healthcare Conference in New York | 2026-06-04 12:50 | 5.45 (+1.30%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 6.08 (+2.36%) | ||
| Leerink Global Healthcare Conference | 2026-03-10 15:00 | 5.92 (+1.28%) | ||
| Annual report for 2025 | 2026-03-10 | 5.92 (+1.28%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-10 | 5.92 (+1.28%) | ||
| Piper Sander 37(th) Annual Healthcare Conference | 2025-12-04 10:00 | 6.63 (+6.08%) | ||
| Guidance call for 2025 | 2025-11-13 09:20 | 8.55 (+3.39%) |
Show
Entries
ImageneBio Inc Frequently Asked Questions
What is ImageneBio Inc(IMA)'s stock price today?
The current price of IMA is $5.59. The 52 week high of IMA is $18.00 and 52 week low is $3.94.
When is next earnings date of ImageneBio Inc(IMA)?
The next earnings date of ImageneBio Inc(IMA) is 2026-11-12 Est..
Does ImageneBio Inc(IMA) pay dividends? If so, how much?
ImageneBio Inc(IMA) does not pay dividend.
Guru Commentaries on NAS:IMA
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on ImageneBio Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers